DE2128461A1 - Pharmazeutisches Präparat - Google Patents
Pharmazeutisches PräparatInfo
- Publication number
- DE2128461A1 DE2128461A1 DE19712128461 DE2128461A DE2128461A1 DE 2128461 A1 DE2128461 A1 DE 2128461A1 DE 19712128461 DE19712128461 DE 19712128461 DE 2128461 A DE2128461 A DE 2128461A DE 2128461 A1 DE2128461 A1 DE 2128461A1
- Authority
- DE
- Germany
- Prior art keywords
- tablet
- weight
- dopa
- polyvinylpyrrolidone
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 36
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 36
- 239000011230 binding agent Substances 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 229920000945 Amylopectin Polymers 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000454 talc Substances 0.000 claims description 7
- 229910052623 talc Inorganic materials 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 3
- 239000002278 tabletting lubricant Substances 0.000 claims 2
- -1 j Substances 0.000 claims 1
- 101100465000 Mus musculus Prag1 gene Proteins 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000007885 tablet disintegrant Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 8
- 239000000975 dye Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 229940060367 inert ingredients Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010041662 Splinter Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4524470A | 1970-06-10 | 1970-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2128461A1 true DE2128461A1 (de) | 1971-12-16 |
Family
ID=21936793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712128461 Pending DE2128461A1 (de) | 1970-06-10 | 1971-06-08 | Pharmazeutisches Präparat |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3632778A (enrdf_load_stackoverflow) |
| BE (1) | BE768269A (enrdf_load_stackoverflow) |
| DE (1) | DE2128461A1 (enrdf_load_stackoverflow) |
| DK (1) | DK126236B (enrdf_load_stackoverflow) |
| ES (1) | ES392066A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2100742B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1296505A (enrdf_load_stackoverflow) |
| NL (1) | NL7107643A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0070178A3 (en) * | 1981-07-13 | 1984-04-25 | E.R. Squibb & Sons, Inc. | Novel bendroflumethiazide formulations |
| EP0275468A1 (de) * | 1986-12-20 | 1988-07-27 | Roche Diagnostics GmbH | Clodronat-haltige Arzneimittel und Verfahren zur Herstellung derselben |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2246013A1 (de) * | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von poroesen tabletten |
| US4017636A (en) * | 1973-10-23 | 1977-04-12 | Abbott Laboratories | Esters of γ-glutamyl amide of dopamine |
| US4209513A (en) * | 1974-02-14 | 1980-06-24 | Burroughs Wellcome Co. | Tablet formulation |
| DE2513940A1 (de) * | 1975-03-29 | 1976-10-14 | Merck Patent Gmbh | Pharmazeutische zubereitung |
| US4097606A (en) * | 1975-10-08 | 1978-06-27 | Bristol-Myers Company | APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same |
| US4143129A (en) * | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
| DE2551446B2 (de) * | 1975-11-15 | 1977-09-15 | Karl Werner Schlüter GmbH, 2000 Ham burg | Verfahren zur herstellung von suppositorien |
| JPS5332111A (en) * | 1976-09-07 | 1978-03-27 | Asahi Chem Ind Co Ltd | Composition for tablet |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| US4195078A (en) * | 1979-03-09 | 1980-03-25 | Eli Lilly And Company | Nabilone granulation |
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4547358A (en) * | 1980-05-06 | 1985-10-15 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| US4465660A (en) * | 1981-04-01 | 1984-08-14 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| JPS5839618A (ja) * | 1981-09-04 | 1983-03-08 | Chugai Pharmaceut Co Ltd | 持続性積層錠剤 |
| CH652025A5 (de) * | 1981-09-14 | 1985-10-31 | Hoffmann La Roche | Pharmazeutisches praeparat. |
| US4736527A (en) * | 1982-12-13 | 1988-04-12 | Konishiroku Photo Industry Co., Ltd. | Apparatus for the heat treatment of powdery material |
| HU209564B (en) * | 1991-01-30 | 1994-07-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing rapide tablets containing levodopa and carbidopa |
| PE20170313A1 (es) * | 2014-05-29 | 2017-04-18 | Novartis Ag | Formulacion de ceritinib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133863A (en) * | 1961-03-10 | 1964-05-19 | Strong Cobb Arner Inc | Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums |
| US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
| US3557292A (en) * | 1968-08-16 | 1971-01-19 | Hoffmann La Roche | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine |
-
1970
- 1970-06-10 US US45244A patent/US3632778A/en not_active Expired - Lifetime
-
1971
- 1971-06-03 NL NL7107643A patent/NL7107643A/xx unknown
- 1971-06-08 DE DE19712128461 patent/DE2128461A1/de active Pending
- 1971-06-09 BE BE768269A patent/BE768269A/xx unknown
- 1971-06-09 DK DK280271AA patent/DK126236B/da unknown
- 1971-06-09 GB GB1296505D patent/GB1296505A/en not_active Expired
- 1971-06-09 ES ES392066A patent/ES392066A1/es not_active Expired
- 1971-06-09 FR FR7120861A patent/FR2100742B1/fr not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0070178A3 (en) * | 1981-07-13 | 1984-04-25 | E.R. Squibb & Sons, Inc. | Novel bendroflumethiazide formulations |
| EP0275468A1 (de) * | 1986-12-20 | 1988-07-27 | Roche Diagnostics GmbH | Clodronat-haltige Arzneimittel und Verfahren zur Herstellung derselben |
Also Published As
| Publication number | Publication date |
|---|---|
| DK126236B (da) | 1973-06-25 |
| FR2100742A1 (enrdf_load_stackoverflow) | 1972-03-24 |
| FR2100742B1 (enrdf_load_stackoverflow) | 1974-09-06 |
| ES392066A1 (es) | 1974-10-16 |
| GB1296505A (enrdf_load_stackoverflow) | 1972-11-15 |
| US3632778A (en) | 1972-01-04 |
| BE768269A (fr) | 1971-12-09 |
| NL7107643A (enrdf_load_stackoverflow) | 1971-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2128461A1 (de) | Pharmazeutisches Präparat | |
| DE69431247T2 (de) | Oxybutyninformulierungen mit gesteuerter freisetzung | |
| DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
| DE69820287T2 (de) | Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst | |
| DE1228029C2 (de) | Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation | |
| DE69802543T2 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| EP2477660B1 (de) | Pharmazeutische zusammensetzung mit den wirkstoffen metformin und sitagliptin oder vildagliptin | |
| DE69400356T2 (de) | Quervernetzte amylose als bindemittel/sprengmittel fuer tabletten | |
| DE2224534B2 (de) | Pharmazeutisches praeparat mit langsamer wirkstoffabgabe | |
| DD292837A5 (de) | Verfahren zur herstellung von cholestyramin-tabletten | |
| DE1279896B (de) | Die Verwendung eines sauren Copolymerisates zur Herstellung von Tabletten mit verlaengerter Wirkstoffabgabe | |
| DE3314003A1 (de) | Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE3435325A1 (de) | Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung | |
| EP0759296A1 (de) | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz | |
| DE1467781A1 (de) | Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe | |
| CH656535A5 (en) | Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water | |
| DE69205579T2 (de) | Virushemmende pharmazeutische zubereitungen zur vaginalen verabreichung. | |
| DE1907546A1 (de) | Schnell zerfallende feste Dosierungseinheiten | |
| DE3150557C2 (enrdf_load_stackoverflow) | ||
| DE1195012B (de) | Verfahren zur Herstellung eines geformten Koerpers zur Abgabe therapeutisch wirksamer Stoffe | |
| DE2446058A1 (de) | Galenische zubereitung fuer die allopurinol-dauertherapie | |
| DE2425764A1 (de) | Tabletten | |
| DE2514982A1 (de) | Tabletten und verfahren zu ihrer herstellung | |
| WO2020148125A1 (de) | Verfahren zur herstellung von leicht einzunehmenden tabletten mit trockenextrakt aus ginkgo biloba blättern |